Phase 3
Completed N=742
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Source: ClinicalTrials.gov NCT00838110 ↗Enrolled (actual)
742
Serious AEs
7.3%
Results posted
Feb 2013
Primary outcomePrimary: Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1 — 0.8; 1.6; 9.5; 10.5 percentage of participants
Summary
This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer's disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks. In Cohort 2 AD subjects (n=500) will be treated with Dimebon 20 mg or placebo TID for 12 weeks After completion of the randomized portion of the study, subjects in both Cohorts will have the opportunity to enroll in a Dimebon open label extension study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 1 |
0.8; 1.6; 9.5; 10.5; 16.7; 12.9 | — |
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Vital Signs in Cohort 2 |
0.8; 0.0; 3.8; 8.3; 9.6; 8.8 | — |
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 1 |
0.0; 0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings in Cohort 2 |
0.9; 0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 1 |
1; 1; 2; 0; 0; 2 | — |
| PRIMARY Percentage of Participants With Abnormal Clinically Significant Laboratory Values in Cohort 2 |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Percentage of Participants With Adverse Events (AEs) in Cohort 1 |
64.6; 64.6 | — |
| PRIMARY Percentage of Participants With Adverse Events (AEs) in Cohort 2 |
55.1; 53.3 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Alzheimer's Disease.
- MMSE 12-26 inclusive.
- If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.
- If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study.
Exclusion Criteria
- Have major structural brain disease (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, or a single lesion in a critical region [e.g., thalamus, hippocampus]).
- Have any major medical illness or unstable medical condition within six months of screening that may interfere with the patient's ability to comply with study procedures and abide by study restrictions.
- Have not been on a stable dose of anti-dementia therapy for at least 60 days prior to dosing or intend to start anti-dementia therapy during the double blind portion of the study.
- Reside in a nursing home or assisted care facility with need for 24-hour care and supervision.
Data sourced from ClinicalTrials.gov (NCT00838110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.